Fig. 1.
Chimeric RTPCR amplified products from co-infections with Mass41 and Ark99 strains of IBV. Using primers described in Table 1, the region targeted was −20 to nt 604 for Ark99 and 580 for Mass41. The reverse transcription assays were initiated with either primer Mass-D or Ark-D. Conditions for PCR with upstream and downstream primers were as follows: 25 cycles at 94°C for 30 s, 50°C for 30 s, and 72°C for 1 min. (a) Amplified products from CEK RNA of uninfected CEK generated with Ark-D, Mass-D, Ark-U, and Mass-U primers in lane 1; of Ark99 infected CEK with Ark-U and Ark-D primers in lane 2; of Ark99 infected CEK with Mass-U and Ark-D primers in lane 3; of Ark99 infected CEK with Ark-U and Mass-D primers in lane 4; of Mass41 infected CEK with Mass-U and Mass-D primers in lane 5; of Mass infected CEK with Mass-U and Ark-D primers in lane 6; of Mass infected CEK with Ark-U and Mass-D primers in lane 7; of mixed Mass and Ark RNA with Mass-U and Ark-D primers in lane 8; of mixed Mass and Ark RNA with Ark-U and Mass-D primers in lane 9; of Mass41 and Ark99 co-infected CEK with Ark-U and Mass-D primers in lane 10; of Mass41 and Ark99 co-infected CEK with Mass-U and Ark-D primers in lane 11, and marker HindIII digested λ DNA ladder marker in lane M with nucleotide size of smaller bands (Gibco-BRL, Grand Island, NY) in lane 12. (b) Amplified chimeric products derived from RNA of Mass41 and Ark99 co-infected CEK cells and allantoic fluid of chicken embryos. HindIII digested λ phage DNA marker is shown in lane M as in 1a. Amplification of viral RNA from co-infected CEK cells with Ark-U and Mass-D primers is shown in lane 1; viral RNA from co-infected CEK cells with Mass-U and Ark-D primers in lane 2; uninfected CEK RNA with Ark-U, Mass-U, Ark-D and Mass-D primers in lane 3; viral RNA from co-infected ECE with Ark-U and Mass-D primers in lane 4; viral RNA from co-infected ECE with Mass-U and Ark-D primers in lane 5; uninfected chicken embryo RNA with Ark-U, Mass-U, Ark-D and Mass-D primers in lane 6. (c) Amplifed products derived from RNA of particles of Mass and Ark vaccine co-infected chicken lungs using Ark-U and Mass-D primers. Products were derived from an expired co-infected chick (lane 1); from two co-infected healthy chicks (lane 2 and 3); from co-infected sick chicks (lane 4, 5 and 6); from chick lung cellular RNA of an uninfected chick (lane 7), and HindIII digested lambda phage DNA marker (lane M) as in 1a.